TP53 and glioblastoma: Importantly, these SAHA analogues downregulate the expression of mTOR signalling components, such as Rictor, whereas p53 and mir143, which targets hexokinase2 (HK2), the first enzyme involved in glycolysis and overexpressed in GBM [199], are upregulated [198].